TipRanks (Tue, 31-Mar 6:25 AM ET)
Tango Therapeutics is the best performing healthcare stock in March
Seeking Alpha News (Mon, 30-Mar 2:10 PM ET)
Veradermics reports Q4 results
Seeking Alpha News (Mon, 30-Mar 7:40 AM ET)
Business Wire (Mon, 30-Mar 7:30 AM ET)
Business Wire (Wed, 18-Mar 7:00 AM ET)
Veradermics to Participate in Upcoming March Investor Conferences
Business Wire (Tue, 3-Mar 7:00 AM ET)
NYSE Content Update: Forgent Power Solutions, Post IPO, to Ring Opening Bell
PRNewswire (Thu, 12-Feb 8:55 AM ET)
Business Wire (Mon, 9-Feb 7:30 AM ET)
Business Wire (Thu, 5-Feb 4:05 PM ET)
NYSE Content Update: Disney Names New CEO After Ringing Bell on Main Street USA
PRNewswire (Wed, 4-Feb 8:55 AM ET)
Veradermics Inc clinical-stage biopharmaceutical company focused on developing therapeutics to address pervasive treatment challenges in highly prevalent aesthetic and dermatological conditions. The company operates in a single segment of allocating resources, assessing performance, and making operating decisions.
Veradermics trades on the NYSE stock market under the symbol MANE.
As of April 2, 2026, MANE stock price climbed to $64.19 with 824,507 million shares trading.
MANE has a market cap of $2.25 billion. This is considered a Mid Cap stock.
The top ETF exchange traded funds that MANE belongs to (by Net Assets): SCHA, LFSC, VTI, ITOT, FPX.
MANE support price is $55.46 and resistance is $62.10 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that MANE shares will trade within this expected range on the day.
